Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
By: GlobenewsWire - 22 Jul 2021Back to overview list

ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
22 JULY 2021 at 3:00 EEST
        

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds increased on 21 July 2021 above five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

 % of shares and voting rights
(total of point A)
% of shares and voting rights through financial instruments
(total of point B)
Total of both in % (points A + B)Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached5.08% shares

 

Below 5% voting rights
0.04% shares

 

Below 5% voting rights
5.13% shares

 

Below 5% voting rights
141,134,278 shares

 

806,258,215 voting rights
Position of previous notification (if applicable)4.99% shares

 

Below 5% voting rights
0.04% shares

 

Below 5% voting rights
5.03% shares

 

Below 5% voting rights
 

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares
ISIN code
Number of shares and voting rights% of shares and voting rights
 Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)
FI0009014377 7,181,075 shares

 

Below 5% voting rights
 5.08% shares

 

Below 5% voting rights
POINT A SUBTOTAL7,181,075 shares

 

Below 5% voting rights
5.08% shares

 

Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rights
Securities LentN/AN/APhysical46,754 shares

Below 5% voting rights
0.03% shares

Below 5% voting rights
CFDN/AN/ACash12,717 shares

 

Below 5% voting rights
0.00% shares

Below 5% voting rights
   POINT B SUBTOTAL59,471 shares

 

Below 5% voting rights
0.04% shares

 

Below 5% voting rights

Orion Corporation

Timo Lappalainen

President and CEO
   Olli Huotari

SVP, Corporate Functions
 

                                                
Contact person:
Terhi Ormio, VP, Communications, Orion Corporation
tel. +358 10 426 4646

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Related companies:Orion Corporation
Copyright 2021 GlobenewsWire Back to overview list
to the top ↑